feedback

Course Director

John P. Leonard, MD
John P. Leonard, MD

Weill Cornell Medicine
New York, New York

Faculty

John C. Byrd
John C. Byrd, MD

The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Professor Dr. med Georg Lenz
Professor Dr. med Georg Lenz

University Hospital Münster
Münster, Germany

David G. Maloney
David G. Maloney, MD, PhD

Fred Hutchinson Cancer Research Center
University of Washington
Cellular Immunotherapy and Bezos Family Immunotherapy Clinic
Seattle Cancer Care Alliance
Seattle, Washington

Accredited by

Penn State College of Medicine

Activity Details

Credit Types:CME
Credit Amount:2.0 Credits
Release Date:2018-Jul-05
Expiration Date:2019-Jul-04
Estimated Time for Completion:120 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

In this activity, which is based on a recent live symposium held at the 2018 American Society of Clinical Oncology Annual Meeting (ASCO 2018), a panel of leading clinicians offers thought-provoking perspectives on the science that has validated newer agent classes in B-cell lymphoma, including therapies such as BTK and PI3K inhibitors, immunomodulators, next-generation antibodies, CAR-T therapy, and other options. The panel also shares insights from their own practice on how best to bridge the divide between clinical research and daily care, focusing on issues such as therapeutic sequencing, awareness and management of adverse events that may limit the benefit of treatment, appropriate dosing in different malignant settings, and the clinical potential of novel strategies, including newer combination approaches, across a range of indolent and aggressive B-cell malignancies.

Upon completion of this activity, participants should be better able to:
  • Summarize updated evidence about novel agent classes in B-cell non-Hodgkin lymphoma, including B-cell receptor inhibitors, apoptosis agents, next-generation antibodies, immunomodulators, and other emerging strategies
  • Discuss patient and prognostic factors that may be used to personalize treatment with newer agent classes in B-cell non-Hodgkin lymphoma
  • Recommend therapy with novel agents for newly diagnosed or relapsed/refractory B-cell non-Hodgkin lymphoma, including in the context of a clinical trial
  • Manage adverse events related to treatment with newer agents in patients with B-cell non-Hodgkin lymphoma

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, hematologist-oncologists, and other clinicians involved in the management of patients with B-cell lymphoma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 05, 2018 - July 04, 2019
Time to Complete: 120 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

John P. Leonard, MD
The Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine
Associate Dean for Clinical Research
Weill Cornell Medicine
New York, New York

John P. Leonard, MD, has no financial interests/relationships or affiliations in relation to this activity.
Consultant and/or Advisor for: ADC Therapeutics SA; AstraZeneca; Bayer Corporation; Biotest Pharmaceuticals Corporation; Bristol-Myers Squibb; Celgene Corporation; Epizyme, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd; Gilead; Juno Pharmaceuticals; Karyopharm Therapeutics; MEI Pharma Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sutro Biopharma, Inc.; and United Therapeutics Corporation.

Faculty

John C. Byrd, MD
Distinguished University Professor
D. Warren Brown Chair of Leukemia Research
Senior Adviser for Cancer Experimental Therapeutics
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

John C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Acerta Pharma; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics, Inc.

Professor Dr. med Georg Lenz
Director of Department of Hematology, Oncology and Pneumology
University Hospital Münster
Münster, Germany

Professor Dr. med Georg Lenz has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca; Bayer AG; Celgene Corporation; F. Hoffmann-La Roche Ltd; and Janssen Pharmaceutica N.V.
Speakers Bureau participant with Bayer AG; Celgene Corporation; F. Hoffmann-La Roche Ltd; and Janssen Pharmaceutica N.V.
Consultant and/or Advisor for: Bayer AG; Bristol-Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd; Gilead; Hexal Pharmaceuticals Inc.; Janssen Pharmaceutica N.V.; NanoString Technologies, Inc.; and Novartis AG.

David G. Maloney, MD, PhD
Member, Clinical Research Division
Medical Director, Cellular Immunotherapy
Leonard and Norma Klorfine Endowed Chair for Clinical Research
Fred Hutchinson Cancer Research Center
Professor of Medicine, Division of Oncology
University of Washington
Service Medical Director
Cellular Immunotherapy and Bezos Family Immunotherapy Clinic
Seattle Cancer Care Alliance
Seattle, Washington

David G. Maloney, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Juno Pharmaceuticals and Kite Pharma, Inc.
Consultant and/or Advisor for: Eureka Therapeutics, Inc.; Genentech, Inc.; Kite Pharma, Inc.; and Novartis Pharmaceuticals Corporation.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6275-19-T.

Providership

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported in part by independent educational grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Celgene Corporation, Incyte Corporation, and TG Therapeutics, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.